Medigene AG (ETR:MDG1 – Get Free Report) shares dropped 6.3% on Wednesday . The company traded as low as €1.76 ($1.87) and last traded at €1.85 ($1.96). Approximately 32,043 shares changed hands during trading, a decline of 90% from the average daily volume of 306,207 shares. The stock had previously closed at €1.97 ($2.10).
Medigene Stock Performance
The stock has a fifty day moving average price of €1.77 and a two-hundred day moving average price of €1.63. The company has a market cap of $45.31 million, a P/E ratio of -2.80, a PEG ratio of 7.12 and a beta of 0.85. The company has a debt-to-equity ratio of 14.00, a current ratio of 2.53 and a quick ratio of 5.85.
Medigene Company Profile
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Further Reading
- Five stocks we like better than Medigene
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- United Airlines Soars on Earnings Beat
- How to Effectively Use the MarketBeat Ratings Screener
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Using the MarketBeat Dividend Tax Calculator
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
